Amundi’s Sage Therapeutics SAGE Stock Holding History

Amundi’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-28,327	Closed	-$166K	–	2238
2024 Q4	$166K	Buy	+28,327	New	+$173K	﹤0.01%	1740
2022 Q4	–	Sell	-2,758	Closed	-$114K	–	1969
2022 Q3	$114K	Hold	2,758	–	–	﹤0.01%	1534
2022 Q2	$97K	Hold	2,758	–	–	﹤0.01%	1451
2022 Q1	$99K	Hold	2,758	–	–	﹤0.01%	1471
2021 Q4	$117K	Hold	2,758	–	–	﹤0.01%	1550
2021 Q3	$122K	Sell	2,758 -197,503	-99%	-$9.06M	﹤0.01%	1499
2021 Q2	$11.4M	Buy	+200,261	New	+$14.2M	0.01%	808

Other funds holding SAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Amundi's SAGE Position: Q1 2025 in Review

Amundi sold out of Sage Therapeutics (SAGE) in Q1 2025, closing a stake of 28,327 shares — an estimated $166K sold.

Amundi first reported a position in SAGE in Q2 2021 and held it in 7 quarters. The position peaked at $11.4M in Q2 2021. 198 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.

Amundi reported no remaining Sage Therapeutics position as of Q1 2025 after selling out during the quarter.
Amundi sold 28,327 Sage Therapeutics shares in Q1 2025, an estimated $166K.
Amundi first reported a position in Sage Therapeutics in Q2 2021 and held it in 7 quarters.
Amundi's Sage Therapeutics position peaked at $11.4M in Q2 2021.
198 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.

Based on Amundi's 13F filing for Q1 2025, filed 15 May 2025.